With some count recovery and intolerance to Inqovi, she completed two cycles of IV decitabine, but a subsequent biopsy showed hypocellular marrow (10% to 15%) with dyspoiesis and increased blasts (20% to 25% by CD34 stain), consistent with AML with mutated TP53. This evidence concerns the gene TP53 and acute myeloid leukemia.